US pharmaceutical company Pfizer is drastically increasing its targets for 2021 after a surprisingly strong start to the year. In the first quarter, Americans benefited greatly from the Corona vaccination, which was marketed with the German company Biontech, but it also grew with other products, such as the fight against cancer.
The Comirnaty Corona vaccine, Pfizer alone, has pumped $ 3.5 billion into its vaults, as the company announced in New York. At the group level, sales rose 45 percent year-on-year to $ 14.6 billion, and net profit rose similarly to $ 4.9 billion.
Spades not enough: Do I need a third dose of the Pfizer vaccine?(00:34)
Shareholders rub their hands
Management around CEO Albert Burla now expects an increase in sales to $ 70.5 to $ 72.5 billion for the full year due to the revised forecast for Comirnaty.
Previously, the $ 61.4 billion cap was still on plan. One-time effects-adjusted earnings per share should appear at $ 3.55 to $ 3.65, after previously promised $ 3.20. (pbe / SDA)
Publication date: May 4, 2021, 3:08 pm
Last updated: May 4, 2021, 45 minutes ago